



May 24, 2017

ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, president and chief executive officer, will present at the upcoming Jefferies 2017 Global Healthcare Conference in New York, NY. The presentation is scheduled for 3:30 pm ET on June 8, 2017.

A webcast of the presentation will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately 90 days.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FR α -positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease.

ImmunoGen's ADC technology is used in Roche's marketed product, Kadcylo[®], in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcylo[®] is a registered trademark of Genentech, a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including mirvetuximab soravtansine, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and other reports filed with the Securities and Exchange Commission.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170524005152/en/>

For Investors

Thrust IR
Monique Allaire, 617-895-9511
monique@thrustir.com

or

For Media

FTI Consulting, Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com

Source: ImmunoGen, Inc.

News Provided by Acquire Media